Join GSK in shaping the future of Australian pharmacy at APP 2018.

 

Explore the Shelf of the Future

Be amongst the first to experience a new instore initiative that looks set to drive category growth and deliver better patient outcomes. The innovative new approach to the pain category fixture that GSK will showcase is based on research and insights gathered from a wide set of locally commissioned qualitative and quantitative sources, as well as the Global Pain Index.

Discover what’s new

Voltaren Emulgel                Zovirax Duo
Powered by consumer insight, GSK is translating consumer and healthcare research into product innovation. See how these products can benefit your customers and drive incremental sales in your pharmacy.

 

Pain management


Voltaren Rapid 25

Did you know that Voltaren Rapid 25 is proven to provide efficacy in not only muscle and back pain, but also in migraine headache, dental pain*, period pain and joint pain 1-5? Come and talk to our team on how Voltaren Rapid 25 could be a trusted and suitable option for your customers looking for a strong pain relief alternative.

*Where inflammation or swelling is present.

 

Learn from an industry leader

In a not to be missed clinical update, Gold Coast Primary Health Network Persistent Pain Clinical Director and PainWISE Managing Director, Joyce McSwan, presents Opportunities for patient-centric analgesic recommendations in pharmacy at 11:00am on Saturday 5 May.

 

Come & talk to us at APP to find out more!
Find GSK at stand 144-149

 


Please review Product Information (PI) before recommending Voltaren Rapid 25. The full PI is available from GlaxoSmithKline Consumer Healthcare on request (FREECALL 1800 028 533).
Voltaren Rapid 25 contains diclofenac potassium 25 mg. Use: For the temporary relief of acute pain where inflammation is present, such as sprains and strains, back and joint pains, migraine headaches and period pain. Adults and children > 14 years: Take 2 tablets initially with liquid, then 1 tablet every 8 hours if necessary (max 8 tablets per day).
Trademarks are owned by or licensed to the (c) 2018 GSK group of companies. GlaxoSmithKline Consumer Healthcare, 82 Hughes Avenue, Ermington NSW 2115. GCB0155. 04/2018. CHANZ/CHVOLT/00XX/18.